publication venue for
- Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers. 84:193-202. 2024
- Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. 81:1411-1427. 2021
- Salicylate enhances the response of prostate cancer to radiotherapy. 79:489-497. 2019
- A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer. 78:1053-1062. 2018
- Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. 78:953-961. 2018
- Elevated C‐Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer. 77:211-221. 2017
- Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America. 75:836-844. 2015
- Construction of tissue micro array from prostate needle biopsies using the vertical clustering re‐arrangement technique. 71:1374-1381. 2011
- Novel biomarkers for risk of prostate cancer: Results from a case–control study. 69:41-48. 2009
- Androgen‐dependent regulation of medium and long chain fatty acids uptake in prostate cancer. 67:1330-1338. 2007
- Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy. 67:162-171. 2007
- Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study. 64:109-115. 2005
- Growth inhibition of prostate cancer xenografts by halofuginone*†. 51:73-83. 2002